ClinVar Miner

Submissions for variant NM_000249.3(MLH1):c.1360G>C (p.Gly454Arg) (rs63750527)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 12
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000587838 SCV000885705 uncertain significance not provided 2017-09-22 criteria provided, single submitter clinical testing The MLH1 c.1360G>C;p.Gly454Arg is reported in the medical literature in individuals with Lynch syndrome (Auclair 2006, Lucci-Cordisco 2006, Loizidou 2014, and Hardt 2011). multiple computational analyses indicate the variant has a neutral effect on the MLH1 protein (Chao 2008). This variant is listed in the dbSNP variant database (rs63750527) and in the Genome Aggregation Database in 28 individuals (28 out of 277032 alleles). The p.Gly454Arg variant is classified by the International Society for Gastrointestinal Hereditary Tumours Incorporated (InSiGHT) as a variant of uncertain significance because there is insufficient evidence about this variant (Variation ID: 89705). The glycine at this position is weakly conserved across species and computational algorithms (AlignGVGD, Polyphen2, SIFT) predict this variant is tolerated. Considering available information, there is insufficient evidence to classify this variant with certainty. References: Chao et al. Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR). Hum Mutat. 2008; 29(6):852-860. Hardt et al. Missense variants in hMLH1 identified in patients from the German HNPCC consortium and functional studies. Fam Cancer. 2011;10(2):273-284. Loizidou et al. The mutational spectrum of Lynch syndrome in cyprus. PLoS One. 2014; 9(8):e105501. Lucci-Cordisco et al. The use of microsatellite instability, immunohistochemistry and other variables in determining the clinical significance of MLH1 and MSH2 unclassified variants in Lynch syndrome. Cancer Biomark. 2006;2(1-2):11-27.
Ambry Genetics RCV000115458 SCV000184486 likely benign Hereditary cancer-predisposing syndrome 2017-08-11 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Co-occurence with a mutation in another gene that clearly explains a proband's phenotype,Structural Evidence,Other data supporting benign classification
Color RCV000115458 SCV000902779 likely benign Hereditary cancer-predisposing syndrome 2016-01-14 criteria provided, single submitter clinical testing
Counsyl RCV000410484 SCV000487861 uncertain significance Lynch syndrome II 2015-11-23 criteria provided, single submitter clinical testing
Fulgent Genetics,Fulgent Genetics RCV000764492 SCV000895563 uncertain significance Turcot syndrome; Muir-Torré syndrome; Lynch syndrome II 2018-10-31 criteria provided, single submitter clinical testing
GeneDx RCV000200984 SCV000149367 likely benign not specified 2017-10-26 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
GeneKor MSA RCV000115458 SCV000822020 uncertain significance Hereditary cancer-predisposing syndrome 2018-08-01 criteria provided, single submitter clinical testing
Integrated Genetics/Laboratory Corporation of America RCV000587838 SCV000696108 uncertain significance not provided 2017-05-26 criteria provided, single submitter clinical testing Variant summary: The c.1360G>C (p.Gly454Arg) variant affects a non-conserved nucleotide. 4/5 in-silico tools predict this variant to be benign. The variant of interest was observed in the large, broad control datasets of ExAC and gnomAD, at a frequencies of 0.00015 (18/121208 and 28/277032 chrs tested), which does not exceed the maximum expected allele frequency for a pathogenic MLH1 variant (0.0007). This variant has been reported in LS patients however without strong evidence for pathogenicity. Multiple clinical laboratories/reputable databases/literatures classified this variant as Likely Benign. Taken together, this variant is classified as variant of uncertain significance until more information becomes available.
Invitae RCV000524233 SCV000166244 likely benign Hereditary nonpolyposis colon cancer 2017-12-19 criteria provided, single submitter clinical testing
Laboratory for Molecular Medicine,Partners HealthCare Personalized Medicine RCV000200984 SCV000539644 uncertain significance not specified 2016-03-31 criteria provided, single submitter clinical testing Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: 1 paper in HGMD; ExAC: 6/16506 South Asian; ClinVar: 4 VUS (1 expert panel)
Mendelics RCV000075179 SCV000838014 uncertain significance Lynch syndrome 2018-07-02 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000200984 SCV000601352 uncertain significance not specified 2016-11-23 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.